HeartWare (HTWR +1.9%) moves higher after an FDA panel says it will review the Premarket Approval application for the company's Ventricular Assist System on April 25. Leerink Swann says the overhang in the shares has been removed following the news, and it believes a Q3 approval and launch is likely.
HeartWare (HTWR +1.9%) moves higher after an FDA panel says it will review the Premarket...
From other sites
Video at CNBC.com (Jun 27, 2016)
at CNBC.com (Mar 13, 2013)
at CNBC.com (Jun 17, 2011)
at CNBC.com (Mar 18, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs